Related Experiment Video
Updated: Oct 8, 2025
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
Preclinical Research Strategy Development for RNAi-Based Therapies in Oncology Using Patient-Centered Information
Abhinav Dey1, Isabelle Balachandran2, Ava Solis3
1MicroCures Inc, Bronx, NY, USA. abhinavdey@gmail.com.
Abstract:
Experimental anticancer agents have a history of failing in the late stages of clinical development, which has led to significantly increased losses to stakeholders during the drug development process. A bioinformatics-based approach to predict and derisk a drug development program can save time, effort, and expenses resulting from failure of experimental anticancer agents in preclinical/early clinical stages. We present a two-step in silico ensemble method, involving the comparison of localized gene expression from surrounding tissue with tumor tissue, and subsequent correlation with patient survival data, which can help predict safety and efficacy for siRNA-based drug delivery to internal cancer tissues. This is achieved by reducing the possible off-target effects due to reduced or minimal expression of the drug target in surrounding tissue, and increasing survival probability for patients whose cancers can be controlled/eliminated by siRNA-mediated inhibition of drug target. This kind of approach can be useful for more efficient drug development efforts in oncology through reduction of investment in expensive experimentation during the discovery and preclinical phases; and ultimately support the intended clinical trial design.
Insights
A new bioinformatics method predicts anticancer drug safety and efficacy by analyzing gene expression in tumors versus surrounding tissues. This approach aims to reduce late-stage failures and improve patient survival in oncology drug development.
Area of Science:
- Bioinformatics
- Oncology
- Drug Development
Background:
- Experimental anticancer agents frequently fail in late-stage clinical trials, causing significant financial losses.
- Predictive bioinformatics approaches can mitigate risks and reduce costs in drug development.
- Current methods lack robust prediction of safety and efficacy for novel therapeutics.
Purpose of the Study:
- To present a novel in silico ensemble method for predicting the safety and efficacy of siRNA-based anticancer drugs.
- To reduce the risk of late-stage drug development failures by identifying potential issues early.
- To enhance the efficiency of oncology drug development and support clinical trial design.
Main Methods:
- A two-step in silico ensemble approach was developed.
- Localized gene expression data from tumor and surrounding tissues were compared.
- Gene expression data were correlated with patient survival data.
Main Results:
- The method predicts safety by minimizing off-target effects through analysis of drug target expression in surrounding tissues.
- The method predicts efficacy by correlating target inhibition with patient survival probability.
- This approach can identify suitable patient populations for siRNA-based therapies.
Conclusions:
- The presented bioinformatics method offers a strategy to predict and derisk anticancer drug development programs.
- This in silico approach can significantly reduce investment in failed preclinical and early clinical experiments.
- The method supports more efficient drug development and optimized clinical trial design in oncology.
